You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMirtazapine
Accession NumberDB00370  (APRD00685)
TypeSmall Molecule
GroupsApproved
DescriptionMirtazapine is an antidepressant introduced by Organon International in 1996 used for the treatment of moderate to severe depression. Mirtazapine has a tetracyclic chemical structure and is classified as a noradrenergic and specific serotonergic antidepressant (NaSSA). It is the only tetracyclic antidepressant that has been approved by the Food and Drug Administration to treat depression. [Wikipedia]
Structure
Thumb
Synonyms
1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)benzazepine
6-Azamianserin
Mepirzapine
Mirtazapin
Mirtazapina
Mirtazapine
Mirtazapinum
External Identifiers
  • Org 3770
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Auro-mirtazapinetablet15 mgoralAuro Pharma Inc2013-10-16Not applicableCanada
Auro-mirtazapinetablet30 mgoralAuro Pharma Inc2013-10-16Not applicableCanada
Auro-mirtazapinetablet45 mgoralAuro Pharma Inc2013-10-16Not applicableCanada
Auro-mirtazapine ODtablet (orally disintegrating)30 mgoralAuro Pharma Inc2010-12-20Not applicableCanada
Auro-mirtazapine ODtablet (orally disintegrating)45 mgoralAuro Pharma Inc2010-12-20Not applicableCanada
Auro-mirtazapine ODtablet (orally disintegrating)15 mgoralAuro Pharma Inc2010-12-20Not applicableCanada
Ava-mirtazapinetablet15 mgoralAvanstra Inc2011-08-182014-08-21Canada
Ava-mirtazapinetablet30 mgoralAvanstra Inc2011-08-182014-08-21Canada
Co Mirtazapinetablet30 mgoralCobalt Pharmaceuticals Company2006-03-232013-07-19Canada
Dom-mirtazapinetablet15 mgoralDominion Pharmacal2006-08-02Not applicableCanada
Dom-mirtazapinetablet30 mgoralDominion Pharmacal2004-05-27Not applicableCanada
Gd-mirtazapine ODtablet (orally disintegrating)45 mgoralGenmed A Division Of Pfizer Canada Inc2012-04-262014-12-08Canada
Gd-mirtazapine ODtablet (orally disintegrating)15 mgoralGenmed A Division Of Pfizer Canada Inc2012-04-262014-12-08Canada
Gd-mirtazapine ODtablet (orally disintegrating)30 mgoralGenmed A Division Of Pfizer Canada Inc2012-05-042014-12-08Canada
Jamp-mirtazapinetablet15 mgoralJamp Pharma Corporation2011-10-13Not applicableCanada
Jamp-mirtazapinetablet30 mgoralJamp Pharma Corporation2011-10-13Not applicableCanada
Mirtazapinetablet, orally disintegrating45 mg/1oralPhysicians Total Care, Inc.2012-12-07Not applicableUs
Mirtazapinetablet, orally disintegrating15 mg/1oralPrasco Laboratories2001-01-12Not applicableUs
Mirtazapinetablet, orally disintegrating30 mg/1oralPrasco Laboratories2001-01-12Not applicableUs
Mirtazapinetablet30 mgoralSanis Health Inc2011-09-21Not applicableCanada
Mirtazapinetablet30 mgoralMeliapharm Inc2004-04-142014-06-25Canada
Mirtazapinetablet, orally disintegrating45 mg/1oralPrasco Laboratories2001-01-12Not applicableUs
Mirtazapinetablet15 mgoralMeliapharm Inc2006-07-212014-06-25Canada
Mirtazapine - 15tablet15 mgoralPro Doc Limitee2007-10-262008-07-10Canada
Mirtazapine - 30tablet30 mgoralPro Doc Limitee2007-10-262008-07-10Canada
Mirtazapine - 45tablet45 mgoralPro Doc Limitee2007-10-262009-07-23Canada
Mylan-mirtazapinetablet15 mgoralMylan Pharmaceuticals Ulc2004-08-17Not applicableCanada
Mylan-mirtazapinetablet30 mgoralMylan Pharmaceuticals Ulc2004-08-17Not applicableCanada
Mylan-mirtazapinetablet45 mgoralMylan Pharmaceuticals Ulc2004-08-17Not applicableCanada
Ntp-mirtazapinetablet30 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-mirtazapine Od Tabletstablet (orally disintegrating)30 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-mirtazapine Od Tabletstablet (orally disintegrating)45 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-mirtazapine Od Tabletstablet (orally disintegrating)15 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Nu-mirtazapinetablet30 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-mirtazapinetablet45 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-mirtazapinetablet15 mgoralNu Pharm IncNot applicableNot applicableCanada
PMS-mirtazapinetablet30 mgoralPharmascience Inc2004-01-14Not applicableCanada
PMS-mirtazapinetablet15 mgoralPharmascience Inc2005-11-30Not applicableCanada
Pro-mirtazapinetablet15 mgoralPro Doc Limitee2008-07-10Not applicableCanada
Pro-mirtazapinetablet30 mgoralPro Doc Limitee2008-07-10Not applicableCanada
Ratio-mirtazapinetablet30 mgoralRatiopharm Inc Division Of Teva Canada Limited2005-09-292014-09-19Canada
Remerontablet, film coated15 mg/1oralOrganon USA Inc.1996-06-14Not applicableUs
Remerontablet30 mgoralMerck Canada Inc2001-05-24Not applicableCanada
Remerontablet, film coated45 mg/1oralOrganon USA Inc.1997-03-11Not applicableUs
Remerontablet, film coated30 mg/1oralOrganon USA Inc.1996-06-14Not applicableUs
Remerontablet, film coated15 mg/1oralPhysicians Total Care, Inc.2001-03-20Not applicableUs
Remeron Rdtablet (orally disintegrating)15 mgoralMerck Canada Inc2003-12-22Not applicableCanada
Remeron Rdtablet (orally disintegrating)30 mgoralMerck Canada Inc2003-12-22Not applicableCanada
Remeron Rdtablet (orally disintegrating)45 mgoralMerck Canada Inc2003-12-22Not applicableCanada
Remeronsoltabtablet, orally disintegrating15 mg/1oralOrganon USA Inc.2001-01-12Not applicableUs
Remeronsoltabtablet, orally disintegrating45 mg/1oralOrganon USA Inc.2001-01-12Not applicableUs
Remeronsoltabtablet, orally disintegrating30 mg/1oralOrganon USA Inc.2001-01-12Not applicableUs
Riva-mirtazapinetablet30 mgoralLaboratoire Riva Inc2005-03-16Not applicableCanada
Sandoz Mirtazapinetablet15 mgoralSandoz Canada Incorporated2004-03-31Not applicableCanada
Sandoz Mirtazapinetablet30 mgoralSandoz Canada Incorporated2004-03-31Not applicableCanada
Sandoz Mirtazapine Fctablet30 mgoralSandoz Canada Incorporated2005-05-092009-08-06Canada
Teva-mirtazapinetablet30 mgoralTeva Canada Limited2005-10-22Not applicableCanada
Teva-mirtazapine ODtablet (orally disintegrating)30 mgoralTeva Canada Limited2006-08-30Not applicableCanada
Teva-mirtazapine ODtablet (orally disintegrating)45 mgoralTeva Canada Limited2006-08-30Not applicableCanada
Teva-mirtazapine ODtablet (orally disintegrating)15 mgoralTeva Canada Limited2006-08-30Not applicableCanada
Zym-mirtazapinetablet30 mgoralZymcan Pharmaceuticals Inc2009-06-232014-06-16Canada
Zym-mirtazapinetablet15 mgoralZymcan Pharmaceuticals Inc2009-06-232014-06-16Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-mirtazapinetablet30 mgoralApotex Inc2006-10-04Not applicableCanada
Apo-mirtazapinetablet45 mgoralApotex Inc2006-10-04Not applicableCanada
Apo-mirtazapinetablet15 mgoralApotex Inc2006-10-04Not applicableCanada
Mirtazapinetablet, film coated30 mg/1oralKAISER FOUNDATION HOSPITALS2010-10-07Not applicableUs
Mirtazapinetablet30 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-11-30Not applicableUs
Mirtazapinetablet, film coated30 mg/1oralbryant ranch prepack2009-08-17Not applicableUs
Mirtazapinetablet, orally disintegrating30 mg/1oralAurobindo Pharma Limited2005-12-08Not applicableUs
Mirtazapinetablet15 mg/1oralCardinal Health2009-11-302015-12-29Us
Mirtazapinetablet, film coated30 mg/1oralLake Erie Medical DBA Quality Care Products LLC2004-10-22Not applicableUs
Mirtazapinetablet15 mg/1oralREMEDYREPACK INC.2011-07-18Not applicableUs
Mirtazapinetablet, film coated30 mg/1oralH.J. Harkins Company, Inc.2009-08-17Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralCardinal Health2003-01-29Not applicableUs
Mirtazapinetablet, film coated30 mg/1oralClinical Solutions Wholesale2007-08-22Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralTeva Pharmaceuticals USA Inc2003-01-29Not applicableUs
Mirtazapinetablet, film coated30 mg/1oralActavis Pharma, Inc.2003-06-19Not applicableUs
Mirtazapinetablet, film coated30 mg/1oralDIRECT RX2014-01-01Not applicableUs
Mirtazapinetablet, film coated30 mg/1oralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2007-09-14Not applicableUs
Mirtazapinetablet, film coated30 mg/1oralAmerican Health Packaging2005-10-31Not applicableUs
Mirtazapinetablet, film coated45 mg/1oralSTAT Rx USA LLC2003-06-01Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralMedsource Pharmaceuticals2009-08-17Not applicableUs
Mirtazapinetablet, film coated30 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-08-28Not applicableUs
Mirtazapinetablet45 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Mirtazapinetablet, film coated30 mg/1oralCitron Pharma LLC2004-10-22Not applicableUs
Mirtazapinetablet, film coated30 mg/1oralPd Rx Pharmaceuticals, Inc.2003-06-19Not applicableUs
Mirtazapinetablet30 mg/1oralREMEDYREPACK INC.2011-09-21Not applicableUs
Mirtazapinetablet, film coated45 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Mirtazapinetablet, film coated45 mg/1oralCardinal Health2009-08-17Not applicableUs
Mirtazapinetablet, film coated45 mg/1oralApotex Corp.2007-08-22Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralMylan Pharmaceuticals Inc.2012-12-28Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralAurolife Pharma LLC2009-08-17Not applicableUs
Mirtazapinetablet, orally disintegrating30 mg/1oralbryant ranch prepack2005-12-08Not applicableUs
Mirtazapinetablet15 mg/1oralContract Pharmacy Services Pa2010-06-30Not applicableUs
Mirtazapinetablet30 mg/1oralSun Pharmaceutical Industries, Inc.2004-04-22Not applicableUs
Mirtazapinetablet30 mg/1oralMc Kesson Contract Packaging2012-01-31Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralAidarex Pharmaceuticals LLC2009-08-17Not applicableUs
Mirtazapinetablet15 mg/1oralREMEDYREPACK INC.2011-03-31Not applicableUs
Mirtazapinetablet, film coated45 mg/1oralMylan Institutional Inc.2003-08-01Not applicableUs
Mirtazapinetablet15 mg/1oralCardinal Health2009-11-30Not applicableUs
Mirtazapinetablet, orally disintegrating45 mg/1oralCitron Pharma LLC2006-02-28Not applicableUs
Mirtazapinetablet, orally disintegrating30 mg/1oralTeva Pharmaceuticals USA Inc2005-09-01Not applicableUs
Mirtazapinetablet, orally disintegrating45 mg/1oralActavis Pharma, Inc.2014-11-13Not applicableUs
Mirtazapinetablet, film coated30 mg/1oralProficient Rx LP2009-08-17Not applicableUs
Mirtazapinetablet, film coated7.5 mg/1oralAurobindo Pharma Limited2004-10-22Not applicableUs
Mirtazapinetablet, film coated45 mg/1oralClinical Solutions Wholesale2007-08-22Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralEon Labs, Inc.2003-06-19Not applicableUs
Mirtazapinetablet, film coated7.5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-08-17Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralbryant ranch prepack2003-06-01Not applicableUs
Mirtazapinetablet, orally disintegrating45 mg/1oralAurobindo Pharma Limited2006-02-28Not applicableUs
Mirtazapinetablet30 mg/1oralCardinal Health2009-11-302015-12-29Us
Mirtazapinetablet, film coated15 mg/1oralRebel Distributors Corp2003-06-01Not applicableUs
Mirtazapinetablet45 mg/1oralREMEDYREPACK INC.2011-07-18Not applicableUs
Mirtazapinetablet15 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Mirtazapinetablet, film coated30 mg/1oralCardinal Health2003-01-29Not applicableUs
Mirtazapinetablet30 mg/1oralPhysicians Total Care, Inc.2005-10-07Not applicableUs
Mirtazapinetablet, film coated45 mg/1oralCitron Pharma LLC2004-10-22Not applicableUs
Mirtazapinetablet, film coated30 mg/1oralTeva Pharmaceuticals USA Inc2003-01-29Not applicableUs
Mirtazapinetablet, film coated45 mg/1oralActavis Pharma, Inc.2003-06-19Not applicableUs
Mirtazapinetablet, film coated45 mg/1oralDIRECT RX2014-01-01Not applicableUs
Mirtazapinetablet, film coated30 mg/1oralTYA Pharmaceuticals2009-08-17Not applicableUs
Mirtazapinetablet, film coated45 mg/1oralAmerican Health Packaging2005-12-21Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralRebel Distributors Corp.2004-10-22Not applicableUs
Mirtazapinetablet45 mg/1oralREMEDYREPACK INC.2010-09-13Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralUnit Dose Services2003-06-19Not applicableUs
Mirtazapinetablet30 mg/1oralContract Pharmacy Services Pa2010-06-30Not applicableUs
Mirtazapinetablet45 mg/1oralSun Pharmaceutical Industries, Inc.2004-04-22Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralAphena Pharma Solutions Tennessee, Llc2009-08-17Not applicableUs
Mirtazapinetablet15 mg/1oralREMEDYREPACK INC.2012-03-26Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Mirtazapinetablet, film coated7.5 mg/1oralCardinal Health2009-08-17Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralREMEDYREPACK INC.2015-03-09Not applicableUs
Mirtazapinetablet, film coated30 mg/1oralMylan Pharmaceuticals Inc.2012-12-28Not applicableUs
Mirtazapinetablet, film coated45 mg/1oralAurolife Pharma LLC2009-08-17Not applicableUs
Mirtazapinetablet, orally disintegrating45 mg/1oralbryant ranch prepack2006-02-28Not applicableUs
Mirtazapinetablet, film coated45 mg/1oralProficient Rx LP2007-08-22Not applicableUs
Mirtazapinetablet, film coated30 mg/1oralAurobindo Pharma Limited2004-10-22Not applicableUs
Mirtazapinetablet15 mg/1oralCardinal Health2004-04-222015-12-29Us
Mirtazapinetablet, film coated30 mg/1oralAidarex Pharmaceuticals LLC2003-06-19Not applicableUs
Mirtazapinetablet30 mg/1oralREMEDYREPACK INC.2011-07-07Not applicableUs
Mirtazapinetablet, film coated45 mg/1oralREMEDYREPACK INC.2013-03-29Not applicableUs
Mirtazapinetablet30 mg/1oralCardinal Health2009-11-30Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralClinical Solutions Wholesale, Llc2007-08-22Not applicableUs
Mirtazapinetablet, orally disintegrating45 mg/1oralTeva Pharmaceuticals USA Inc2005-09-01Not applicableUs
Mirtazapinetablet45 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-11-30Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralCardinal Health2009-08-17Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralApotex Corp.2007-08-22Not applicableUs
Mirtazapinetablet, film coated30 mg/1oralEon Labs, Inc.2003-06-19Not applicableUs
Mirtazapinetablet, film coated7.5 mg/1oralAurolife Pharma LLC2009-08-17Not applicableUs
Mirtazapinetablet, film coated45 mg/1oralbryant ranch prepack2009-08-17Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralAurobindo Pharma Limited2004-10-22Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralMajor Pharmaceuticals2007-08-22Not applicableUs
Mirtazapinetablet, film coated30 mg/1oralRebel Distributors Corp2003-06-01Not applicableUs
Mirtazapinetablet45 mg/1oralREMEDYREPACK INC.2011-07-22Not applicableUs
Mirtazapinetablet30 mg/1oralREMEDYREPACK INC.2010-11-10Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralMylan Institutional Inc.2003-08-01Not applicableUs
Mirtazapinetablet15 mg/1oralPhysicians Total Care, Inc.2006-07-14Not applicableUs
Mirtazapinetablet, orally disintegrating15 mg/1oralCitron Pharma LLC2005-12-08Not applicableUs
Mirtazapinetablet, film coated45 mg/1oralTeva Pharmaceuticals USA Inc2003-06-19Not applicableUs
Mirtazapinetablet, orally disintegrating15 mg/1oralActavis Pharma, Inc.2014-02-11Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralProficient Rx LP2007-08-22Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralTYA Pharmaceuticals2007-08-22Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralPreferred Pharmaceuticals, Inc.2015-04-16Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralAvera Mc Kennan Hospital2015-03-05Not applicableUs
Mirtazapinetablet, film coated30 mg/1oralRebel Distributors Corp.2004-10-22Not applicableUs
Mirtazapinetablet, orally disintegrating45 mg/1oralbryant ranch prepack2005-12-08Not applicableUs
Mirtazapinetablet45 mg/1oralContract Pharmacy Services Pa2010-06-30Not applicableUs
Mirtazapinetablet7.5 mg/1oralSun Pharmaceutical Industries, Inc.2004-04-22Not applicableUs
Mirtazapinetablet, film coated30 mg/1oralAphena Pharma Solutions Tennessee, Llc2009-08-17Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralREMEDYREPACK INC.2012-09-10Not applicableUs
Mirtazapinetablet15 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Mirtazapinetablet, film coated7.5 mg/1oralCitron Pharma LLC2004-10-22Not applicableUs
Mirtazapinetablet, film coated45 mg/1oralREMEDYREPACK INC.2015-03-09Not applicableUs
Mirtazapinetablet, film coated45 mg/1oralMylan Pharmaceuticals Inc.2012-12-28Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralSTAT Rx USA LLC2003-06-01Not applicableUs
Mirtazapinetablet, film coated30 mg/1oralProficient Rx LP2007-08-22Not applicableUs
Mirtazapinetablet, orally disintegrating15 mg/1oralAurobindo Pharma Limited2005-12-08Not applicableUs
Mirtazapinetablet30 mg/1oralCardinal Health2004-04-222015-12-29Us
Mirtazapinetablet, film coated45 mg/1oralLake Erie Medical DBA Quality Care Products LLC2011-02-19Not applicableUs
Mirtazapinetablet30 mg/1oralREMEDYREPACK INC.2011-07-12Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralREMEDYREPACK INC.2013-05-08Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralCardinal Health2007-08-22Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralClinical Solutions Wholesale2003-06-19Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralKAISER FOUNDATION HOSPITALS2011-05-24Not applicableUs
Mirtazapinetablet15 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2009-11-30Not applicableUs
Mirtazapinetablet, film coated45 mg/1oralRebel Distributors Corp2003-06-19Not applicableUs
Mirtazapinetablet15 mg/1oralREMEDYREPACK INC.2011-08-04Not applicableUs
Mirtazapinetablet, film coated30 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Mirtazapinetablet, film coated30 mg/1oralCardinal Health2009-08-17Not applicableUs
Mirtazapinetablet, film coated30 mg/1oralApotex Corp.2007-08-22Not applicableUs
Mirtazapinetablet, film coated45 mg/1oralEon Labs, Inc.2003-06-19Not applicableUs
Mirtazapinetablet, film coated30 mg/1oralAurolife Pharma LLC2009-08-17Not applicableUs
Mirtazapinetablet, orally disintegrating15 mg/1oralbryant ranch prepack2005-12-08Not applicableUs
Mirtazapinetablet, film coated45 mg/1oralAurobindo Pharma Limited2004-10-22Not applicableUs
Mirtazapinetablet15 mg/1oralSun Pharmaceutical Industries, Inc.2004-04-22Not applicableUs
Mirtazapinetablet, film coated45 mg/1oralRebel Distributors Corp.2004-10-22Not applicableUs
Mirtazapinetablet30 mg/1oralREMEDYREPACK INC.2011-03-30Not applicableUs
Mirtazapinetablet, film coated30 mg/1oralMylan Institutional Inc.2003-08-01Not applicableUs
Mirtazapinetablet45 mg/1oralPhysicians Total Care, Inc.2007-08-23Not applicableUs
Mirtazapinetablet, orally disintegrating30 mg/1oralCitron Pharma LLC2005-12-08Not applicableUs
Mirtazapinetablet, orally disintegrating15 mg/1oralTeva Pharmaceuticals USA Inc2005-09-01Not applicableUs
Mirtazapinetablet, orally disintegrating30 mg/1oralActavis Pharma, Inc.2014-02-11Not applicableUs
Mirtazapinetablet, film coated30 mg/1oralProficient Rx LP2003-01-29Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralTYA Pharmaceuticals2003-06-19Not applicableUs
Mirtazapinetablet15 mg/1oralMc Kesson Contract Packaging2011-10-26Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralAvera Mc Kennan Hospital2015-03-17Not applicableUs
Mirtazapinetablet, film coated30 mg/1oralSTAT Rx USA LLC2003-06-01Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralMc Kesson Packaging Services Business Unit Of Mc Kesson Corporation2007-08-07Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralAmerican Health Packaging2005-10-31Not applicableUs
Mirtazapinetablet, film coated45 mg/1oralAphena Pharma Solutions Tennessee, Llc2009-08-17Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralLake Erie Medical DBA Quality Care Products LLC2009-08-17Not applicableUs
Mirtazapinetablet30 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralCitron Pharma LLC2004-10-22Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralDIRECT RX2015-01-01Not applicableUs
Mirtazapinetablet, film coated15 mg/1oralActavis Pharma, Inc.2003-06-19Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AvanzaSchering-Plough
AxitAlphapharm
Mirtabeneratiopharm
MirtazPinewood
MirtazonSchering-Plough
NorsetMSD France
PromyrtilSchering-Plough
RemergilMerck Sharp & Dohme
RemergonOrganon
Remeron SolTabNot Available
RexerSchering-Plough
ZispinOrganon
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIA051Q2099Q
CAS number85650-52-8
WeightAverage: 265.3529
Monoisotopic: 265.157897623
Chemical FormulaC17H19N3
InChI KeyInChIKey=RONZAEMNMFQXRA-UHFFFAOYSA-N
InChI
InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3
IUPAC Name
5-methyl-2,5,19-triazatetracyclo[13.4.0.0²,⁷.0⁸,¹³]nonadeca-1(15),8,10,12,16,18-hexaene
SMILES
CN1CCN2C(C1)C1=CC=CC=C1CC1=C2N=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as piperazinoazepines. These are compounds containing a piperazinoazepine skeleton, which consists of an azepie ring fused to a piperazine.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPiperazinoazepines
Sub ClassNot Available
Direct ParentPiperazinoazepines
Alternative Parents
Substituents
  • Piperazino-azepine
  • Benzazepine
  • Dialkylarylamine
  • Aralkylamine
  • N-alkylpiperazine
  • N-methylpiperazine
  • Azepine
  • Imidolactam
  • Benzenoid
  • Pyridine
  • Piperazine
  • 1,4-diazinane
  • Heteroaromatic compound
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of major depressive disorder.
PharmacodynamicsMirtazapine, an antidepressant of the piperazinoazepine class, is a tetracyclic compound with an anxiolytic effect. Mirtazapine has fewer ADRs than tricyclic antidepressants and is better tolerated. Selective blockade of specific serotonin receptors by mirtazapine likey minimizes side effects typical of other antidepressants.
Mechanism of actionMirtazapine acts as an antagonist at central pre-synaptic alpha(2)-receptors, inhibiting negative feedback to the presynaptic nerve and causing an increase in NE release. Blockade of heteroreceptors, alpha(2)-receptors contained in serotenergic neurons, enhances the release of 5-HT, increasing the interactions between 5-HT and 5-HT1 receptors and contributing to the anxiolytic effects of mirtazapine. Mirtazapine also acts as a weak antagonist at 5-HT1 receptors and as a potent antagonist at 5-HT2 (particularly subtypes 2A and 2C) and 5-HT3 receptors. Blockade of these receptors may explain the lower incidence of adverse effects such as anxiety, insomnia, and nausea. Mirtazapine also exhibits significant antagonism at H1-receptors, resulting in sedation. Mirtazapine has no effects on the reuptake of either NE or 5-HT and has only minimal activity at dopaminergic and muscarinic receptors.
Related Articles
AbsorptionRapid and complete, but, due to first-pass metabolism, absolute bioavailability is 50%.
Volume of distributionNot Available
Protein binding85%
Metabolism

Mirtazapine is extensively metabolized by demethylation and hydroxylation followed by glucuronide conjugation. Cytochrome P450 2D6 and cytochrome P450 1A2 are involved in formation of the 8-hydroxy metabolite of mirtazapine, and cytochrome P450 3A4 is responsible for the formation of the N-desmethyl and N-oxide metabolites. Several metabolites possess pharmacological activity, but plasma levels are very low.

SubstrateEnzymesProduct
Mirtazapine
mirtazapine-N-oxideDetails
Mirtazapine
N-desmethylmirtazapineDetails
Mirtazapine
8-hydroxymirtazapineDetails
Route of eliminationThis drug is known to be substantially excreted by the kidney (75%).
Half life20-40 hours
ClearanceNot Available
ToxicitySymptoms of overdose include disorientation, drowsiness, impaired memory, and tachycardia. LD50 is 600-720mg/kg (oral, mice) and 320-490mg/kg (oral, rat) [PMID: 10333982]
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9873
Blood Brain Barrier+0.9855
Caco-2 permeable+0.7283
P-glycoprotein substrateSubstrate0.8462
P-glycoprotein inhibitor IInhibitor0.6148
P-glycoprotein inhibitor IINon-inhibitor0.8975
Renal organic cation transporterInhibitor0.7956
CYP450 2C9 substrateNon-substrate0.7988
CYP450 2D6 substrateSubstrate0.7894
CYP450 3A4 substrateNon-substrate0.5148
CYP450 1A2 substrateInhibitor0.8503
CYP450 2C9 inhibitorNon-inhibitor0.6675
CYP450 2D6 inhibitorInhibitor0.7222
CYP450 2C19 inhibitorNon-inhibitor0.6206
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6031
Ames testNon AMES toxic0.8079
CarcinogenicityNon-carcinogens0.9742
BiodegradationNot ready biodegradable0.9919
Rat acute toxicity2.5197 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7532
hERG inhibition (predictor II)Inhibitor0.7455
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Actavis totowa llc
  • Aurobindo pharma ltd inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
  • Organon usa inc
  • Actavis elizabeth llc
  • Alphapharm party ltd
  • Apotex inc etobicoke site
  • Aurobindo pharma ltd
  • Caraco pharmaceutical laboratories ltd
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Roxane laboratories inc
  • Sandoz inc
  • Watson laboratories inc florida
Packagers
Dosage forms
FormRouteStrength
Tabletoral15 mg/1
Tabletoral30 mg/1
Tabletoral45 mg/1
Tabletoral7.5 mg/1
Tablet, film coatedoral7.5 mg/1
Tabletoral45 mg
Tabletoral30 mg
Tablet, film coatedoral15 mg/1
Tablet, film coatedoral30 mg/1
Tablet, film coatedoral45 mg/1
Tablet (orally disintegrating)oral15 mg
Tablet (orally disintegrating)oral30 mg
Tablet (orally disintegrating)oral45 mg
Tablet, orally disintegratingoral15 mg/1
Tablet, orally disintegratingoral30 mg/1
Tablet, orally disintegratingoral45 mg/1
Tabletoral15 mg
Prices
Unit descriptionCostUnit
Remeron SolTab 30 45 mg Dispersible Tablet Box114.4USD box
Remeron SolTab 30 15 mg Dispersible Tablet Box107.58USD box
Remeron SolTab 30 30 mg Dispersible Tablet Box107.27USD box
Mirtazapine 30 45 mg Dispersible Tablet Box88.95USD box
Mirtazapine 30 30 mg Dispersible Tablet Box83.48USD box
Mirtazapine 30 15 mg Dispersible Tablet Box81.02USD box
Remeron 45 mg tablet4.61USD tablet
Remeron 15 mg tablet4.42USD tablet
Remeron 45 mg soltab3.57USD tablet
Remeron 30 mg soltab3.55USD tablet
Remeron 30 mg tablet3.47USD tablet
Remeron 15 mg soltab3.26USD tablet
Mirtazapine 45 mg tablet2.91USD tablet
Mirtazapine 30 mg tablet2.85USD tablet
Mirtazapine 15 mg tablet2.77USD tablet
Mirtazapine 7.5 mg tablet2.56USD tablet
Apo-Mirtazapine 30 mg Tablet0.73USD tablet
Mylan-Mirtazapine 30 mg Tablet0.73USD tablet
Novo-Mirtazapine 30 mg Tablet0.73USD tablet
Phl-Mirtazapine 30 mg Tablet0.73USD tablet
Pms-Mirtazapine 30 mg Tablet0.73USD tablet
Ratio-Mirtazapine 30 mg Tablet0.73USD tablet
Sandoz Mirtazapine 30 mg Tablet0.73USD tablet
Pms-Mirtazapine 15 mg Tablet0.39USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2386547 No2010-06-082020-10-09Canada
US5178878 No1993-01-122010-01-12Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point114-116 °CNot Available
water solubilitySlightNot Available
logP2.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.1 mg/mLALOGPS
logP2.9ALOGPS
logP3.21ChemAxon
logS-2.4ALOGPS
pKa (Strongest Basic)6.67ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area19.37 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity82.66 m3·mol-1ChemAxon
Polarizability30.35 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Leonid Metzger, “Methods for the preparation of mirtazapine intermediates.” U.S. Patent US20020165238, issued November 07, 2002.

US20020165238
General References
  1. Gillman PK: A systematic review of the serotonergic effects of mirtazapine in humans: implications for its dual action status. Hum Psychopharmacol. 2006 Mar;21(2):117-25. [PubMed:16342227 ]
  2. Burrows GD, Kremer CM: Mirtazapine: clinical advantages in the treatment of depression. J Clin Psychopharmacol. 1997 Apr;17 Suppl 1:34S-39S. [PubMed:9090576 ]
  3. Velazquez C, Carlson A, Stokes KA, Leikin JB: Relative safety of mirtazapine overdose. Vet Hum Toxicol. 2001 Dec;43(6):342-4. [PubMed:11757992 ]
  4. Gorman JM: Mirtazapine: clinical overview. J Clin Psychiatry. 1999;60 Suppl 17:9-13; discussion 46-8. [PubMed:10446735 ]
  5. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU: Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2005 Nov;19(6):567-96. [PubMed:16272179 ]
  6. Fawcett J, Barkin RL: Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord. 1998 Dec;51(3):267-85. [PubMed:10333982 ]
External Links
ATC CodesN06AX11
AHFS Codes
  • 28:16.04.92
PDB EntriesNot Available
FDA labelDownload (904 KB)
MSDSDownload (57.2 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe serum concentration of Mirtazapine can be increased when it is combined with 1,10-Phenanthroline.
3,4-DichloroisocoumarinThe serum concentration of Mirtazapine can be increased when it is combined with 3,4-Dichloroisocoumarin.
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Mirtazapine.
3,4-MethylenedioxyamphetamineMirtazapine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may decrease the sedative activities of Mirtazapine.
3,4-MethylenedioxymethamphetamineMirtazapine may increase the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe serum concentration of Mirtazapine can be increased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.
4-MethoxyamphetamineThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Mirtazapine.
7-Nitroindazole7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Mirtazapine is combined with 7-Nitroindazole.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the central neurotoxic activities of Mirtazapine.
AbirateroneThe serum concentration of Mirtazapine can be increased when it is combined with Abiraterone.
AcenocoumarolMirtazapine may increase the anticoagulant activities of Acenocoumarol.
AcepromazineAcepromazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
AcepromazineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Acepromazine.
AceprometazineAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
AceprometazineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Aceprometazine.
AcetophenazineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Acetophenazine.
adipiplonadipiplon may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
adipiplonThe risk or severity of adverse effects can be increased when Mirtazapine is combined with adipiplon.
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Mirtazapine.
AgomelatineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
AgomelatineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Agomelatine.
AlfaxaloneAlfaxalone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Alfaxalone.
AlfentanilAlfentanil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
AlfentanilThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Alfentanil.
AlmotriptanThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Almotriptan.
AlogliptinThe serum concentration of Mirtazapine can be increased when it is combined with Alogliptin.
Alpha-1-proteinase inhibitorThe serum concentration of Mirtazapine can be increased when it is combined with Alpha-1-proteinase inhibitor.
AlphacetylmethadolAlphacetylmethadol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Alphacetylmethadol.
AlprazolamAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
AlprazolamThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Alprazolam.
AltretamineAltretamine may increase the orthostatic hypotensive activities of Mirtazapine.
AmiodaroneMirtazapine may increase the QTc-prolonging activities of Amiodarone.
AmiodaroneThe metabolism of Mirtazapine can be decreased when combined with Amiodarone.
AmisulprideAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
AmisulprideThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Amisulpride.
AmitriptylineAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
AmitriptylineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Amitriptyline.
AmobarbitalAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
AmobarbitalThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Amobarbital.
AmoxapineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
AmoxapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Amoxapine.
AmperozideAmperozide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
AmperozideThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Amperozide.
AmphetamineAmphetamine may decrease the sedative activities of Mirtazapine.
AmphetamineMirtazapine may increase the stimulatory activities of Amphetamine.
AmprenavirThe serum concentration of Mirtazapine can be increased when it is combined with Amprenavir.
AnagrelideMirtazapine may increase the QTc-prolonging activities of Anagrelide.
Antithrombin III humanThe serum concentration of Mirtazapine can be increased when it is combined with Antithrombin III human.
ApixabanThe serum concentration of Mirtazapine can be increased when it is combined with Apixaban.
ApomorphineThe therapeutic efficacy of Apomorphine can be decreased when used in combination with Mirtazapine.
ApraclonidineThe therapeutic efficacy of Apraclonidine can be decreased when used in combination with Mirtazapine.
AprepitantThe serum concentration of Mirtazapine can be increased when it is combined with Aprepitant.
AprotininThe serum concentration of Mirtazapine can be increased when it is combined with Aprotinin.
ArbutamineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Arbutamine.
ArformoterolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Arformoterol.
ArgatrobanThe serum concentration of Mirtazapine can be increased when it is combined with Argatroban.
AripiprazoleAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
AripiprazoleThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Aripiprazole.
Arsenic trioxideMirtazapine may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherMirtazapine may increase the QTc-prolonging activities of Artemether.
ArtemetherThe metabolism of Mirtazapine can be decreased when combined with Artemether.
ArticaineArticaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ArticaineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Articaine.
AsenapineAsenapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
AsenapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Asenapine.
AsunaprevirThe serum concentration of Mirtazapine can be increased when it is combined with Asunaprevir.
AtazanavirThe serum concentration of Mirtazapine can be increased when it is combined with Atazanavir.
AtomoxetineThe metabolism of Mirtazapine can be decreased when combined with Atomoxetine.
AzaperoneAzaperone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
AzaperoneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Azaperone.
AzelastineAzelastine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
AzithromycinMirtazapine may increase the QTc-prolonging activities of Azithromycin.
AzithromycinThe metabolism of Mirtazapine can be decreased when combined with Azithromycin.
BaclofenBaclofen may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
BaclofenThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Baclofen.
BambuterolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Bambuterol.
BarbitalBarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
BarbitalThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Barbital.
BatimastatThe serum concentration of Mirtazapine can be increased when it is combined with Batimastat.
BedaquilineMirtazapine may increase the QTc-prolonging activities of Bedaquiline.
BenazeprilThe serum concentration of Mirtazapine can be increased when it is combined with Benazepril.
BenmoxinBenmoxin may increase the central neurotoxic activities of Mirtazapine.
BenzamidineThe serum concentration of Mirtazapine can be increased when it is combined with Benzamidine.
BenzocaineBenzocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
BenzocaineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Benzocaine.
BenzphetamineBenzphetamine may decrease the sedative activities of Mirtazapine.
BenzphetamineMirtazapine may increase the stimulatory activities of Benzphetamine.
Benzyl alcoholBenzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Benzyl alcohol.
Benzylpenicilloyl PolylysineMirtazapine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Mirtazapine.
BetaxololThe metabolism of Mirtazapine can be decreased when combined with Betaxolol.
BethanidineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Mirtazapine.
BexaroteneThe serum concentration of Mirtazapine can be decreased when it is combined with Bexarotene.
BifeprunoxThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Bifeprunox.
BivalirudinThe serum concentration of Mirtazapine can be increased when it is combined with Bivalirudin.
BoceprevirThe serum concentration of Mirtazapine can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Mirtazapine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Mirtazapine can be decreased when it is combined with Bosentan.
BrexpiprazoleBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
BrimonidineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Mirtazapine.
BromazepamBromazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
BromazepamThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Bromazepam.
BromocriptineThe therapeutic efficacy of Bromocriptine can be decreased when used in combination with Mirtazapine.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Mirtazapine.
BrompheniramineBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
BrompheniramineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Brompheniramine.
BrotizolamBrotizolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
BrotizolamThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Brotizolam.
BupivacaineBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
BupivacaineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Bupivacaine.
BuprenorphineBuprenorphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
BuprenorphineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Buprenorphine.
BupropionThe metabolism of Mirtazapine can be decreased when combined with Bupropion.
BuspironeBuspirone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
BuspironeThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Buspirone.
ButabarbitalButabarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ButabarbitalThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Butabarbital.
ButacaineButacaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ButacaineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Butacaine.
ButalbitalButalbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ButalbitalThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Butalbital.
ButambenButamben may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ButambenThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Butamben.
ButethalButethal may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ButethalThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Butethal.
ButorphanolButorphanol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ButorphanolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Butorphanol.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Mirtazapine.
CaffeineThe metabolism of Mirtazapine can be decreased when combined with Caffeine.
CandoxatrilThe serum concentration of Mirtazapine can be increased when it is combined with Candoxatril.
CapecitabineThe metabolism of Mirtazapine can be decreased when combined with Capecitabine.
CaptoprilThe serum concentration of Mirtazapine can be increased when it is combined with Captopril.
CarbamazepineCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
CarbamazepineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Carbamazepine.
CarbinoxamineCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Carbinoxamine.
CarfentanilCarfentanil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
CarfentanilThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Carfentanil.
CariprazineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Cariprazine.
CarisoprodolCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
CarisoprodolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Carisoprodol.
CaroxazoneCaroxazone may increase the central neurotoxic activities of Mirtazapine.
CelecoxibThe metabolism of Mirtazapine can be decreased when combined with Celecoxib.
CeliprololThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Celiprolol.
CeritinibThe serum concentration of Mirtazapine can be increased when it is combined with Ceritinib.
CeritinibMirtazapine may increase the QTc-prolonging activities of Ceritinib.
CetirizineCetirizine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
CetirizineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Cetirizine.
Chloral hydrateChloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Chloral hydrate.
ChlordiazepoxideChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Chlordiazepoxide.
ChlormezanoneChlormezanone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Chlormezanone.
ChloroprocaineChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ChloroprocaineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Chloroprocaine.
ChloroquineMirtazapine may increase the QTc-prolonging activities of Chloroquine.
ChloroquineThe metabolism of Mirtazapine can be decreased when combined with Chloroquine.
ChlorphenamineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Chlorphenamine.
ChlorphentermineChlorphentermine may decrease the sedative activities of Mirtazapine.
ChlorphentermineMirtazapine may increase the stimulatory activities of Chlorphentermine.
ChlorpromazineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Chlorpromazine.
ChlorprothixeneChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Chlorprothixene.
ChlorzoxazoneChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Mirtazapine can be decreased when combined with Cholecalciferol.
ChymostatinThe serum concentration of Mirtazapine can be increased when it is combined with Chymostatin.
CilastatinThe serum concentration of Mirtazapine can be increased when it is combined with Cilastatin.
CilazaprilThe serum concentration of Mirtazapine can be increased when it is combined with Cilazapril.
CimetidineThe metabolism of Mirtazapine can be decreased when combined with Cimetidine.
CinacalcetThe serum concentration of Mirtazapine can be increased when it is combined with Cinacalcet.
CinchocaineCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
CinchocaineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Cinchocaine.
CiprofloxacinMirtazapine may increase the QTc-prolonging activities of Ciprofloxacin.
CirazolineMirtazapine may increase the vasopressor activities of Cirazoline.
CisaprideMirtazapine may increase the QTc-prolonging activities of Cisapride.
CitalopramThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Citalopram.
CitalopramThe metabolism of Mirtazapine can be decreased when combined with Citalopram.
ClarithromycinMirtazapine may increase the QTc-prolonging activities of Clarithromycin.
ClarithromycinThe metabolism of Mirtazapine can be decreased when combined with Clarithromycin.
ClemastineClemastine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ClemastineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Clemastine.
ClenbuterolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Clenbuterol.
ClidiniumClidinium may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ClidiniumThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Clidinium.
ClobazamClobazam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ClobazamThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Clobazam.
clomethiazoleclomethiazole may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
clomethiazoleThe risk or severity of adverse effects can be increased when Mirtazapine is combined with clomethiazole.
ClomipramineClomipramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ClomipramineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Clomipramine.
ClonazepamClonazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ClonazepamThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Clonazepam.
ClonidineClonidine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ClonidineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Mirtazapine.
ClopidogrelThe metabolism of Mirtazapine can be decreased when combined with Clopidogrel.
ClorazepateClorazepate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ClorazepateThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Clorazepate.
ClotrimazoleThe metabolism of Mirtazapine can be decreased when combined with Clotrimazole.
ClozapineClozapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ClozapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Clozapine.
CobicistatThe serum concentration of Mirtazapine can be increased when it is combined with Cobicistat.
CocaineCocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
CocaineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Cocaine.
CodeineCodeine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
CodeineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Codeine.
ConivaptanThe serum concentration of Mirtazapine can be increased when it is combined with Conivaptan.
CrizotinibMirtazapine may increase the QTc-prolonging activities of Crizotinib.
CrizotinibThe metabolism of Mirtazapine can be decreased when combined with Crizotinib.
CyamemazineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Cyamemazine.
CyclizineCyclizine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
CyclizineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Cyclizine.
CyclobenzaprineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Cyclobenzaprine.
CyclosporineThe metabolism of Mirtazapine can be decreased when combined with Cyclosporine.
CyproheptadineCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
CyproheptadineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Mirtazapine can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateThe serum concentration of Mirtazapine can be increased when it is combined with Dabigatran etexilate.
DabrafenibThe serum concentration of Mirtazapine can be decreased when it is combined with Dabrafenib.
DantroleneDantrolene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DantroleneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Dantrolene.
DapiprazoleDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DapiprazoleThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Dapiprazole.
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Mirtazapine.
DarifenacinThe metabolism of Mirtazapine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Mirtazapine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Mirtazapine can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Mirtazapine can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Mirtazapine can be decreased when combined with Delavirdine.
deramciclanederamciclane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
deramciclaneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with deramciclane.
DesfluraneDesflurane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DesfluraneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Desflurane.
DesipramineDesipramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DesipramineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Desipramine.
DesloratadineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DesloratadineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Desloratadine.
DesmopressinThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Desmopressin.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Desvenlafaxine.
DetomidineDetomidine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DetomidineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Detomidine.
DexamethasoneThe serum concentration of Mirtazapine can be decreased when it is combined with Dexamethasone.
DexbrompheniramineDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Dexbrompheniramine.
DexmedetomidineDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DexmedetomidineThe therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Mirtazapine.
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Mirtazapine.
DextroamphetamineDextroamphetamine may decrease the sedative activities of Mirtazapine.
DextroamphetamineMirtazapine may increase the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Dextromethorphan.
DextromoramideDextromoramide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DextromoramideThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Dextromoramide.
DextropropoxypheneDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Dextropropoxyphene.
DezocineDezocine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DezocineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Dezocine.
DiazepamDiazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DiazepamThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Diazepam.
DicoumarolMirtazapine may increase the anticoagulant activities of Dicoumarol.
DifenoxinDifenoxin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DifenoxinThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Difenoxin.
DihydrocodeineDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Dihydrocodeine.
DihydroergotamineThe therapeutic efficacy of Dihydroergotamine can be decreased when used in combination with Mirtazapine.
DihydroergotamineThe metabolism of Mirtazapine can be decreased when combined with Dihydroergotamine.
DihydroetorphineDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Dihydroetorphine.
DihydromorphineDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DihydromorphineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Dihydromorphine.
DiltiazemThe metabolism of Mirtazapine can be decreased when combined with Diltiazem.
DimenhydrinateDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Dimenhydrinate.
DiphenhydramineDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Diphenhydramine.
DiphenoxylateDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Diphenoxylate.
DipivefrinThe therapeutic efficacy of Dipivefrin can be decreased when used in combination with Mirtazapine.
DisopyramideMirtazapine may increase the QTc-prolonging activities of Disopyramide.
DobutamineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Dobutamine.
DofetilideMirtazapine may increase the QTc-prolonging activities of Dofetilide.
DolasetronMirtazapine may increase the QTc-prolonging activities of Dolasetron.
DolasetronDolasetron may increase the serotonergic activities of Mirtazapine.
DomperidoneMirtazapine may increase the QTc-prolonging activities of Domperidone.
DoramectinDoramectin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DoramectinThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Doramectin.
DoxepinDoxepin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DoxepinThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Doxepin.
DoxycyclineThe metabolism of Mirtazapine can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DoxylamineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Doxylamine.
DPDPEDPDPE may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DPDPEThe risk or severity of adverse effects can be increased when Mirtazapine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DronedaroneThe metabolism of Mirtazapine can be decreased when combined with Dronedarone.
DronedaroneMirtazapine may increase the QTc-prolonging activities of Dronedarone.
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DroperidolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Droperidol.
DrotebanolDrotebanol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DrotebanolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Drotebanol.
DroxidopaThe therapeutic efficacy of Droxidopa can be decreased when used in combination with Mirtazapine.
DuloxetineThe metabolism of Mirtazapine can be decreased when combined with Duloxetine.
DuloxetineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Duloxetine.
DyclonineDyclonine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
DyclonineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Dyclonine.
EcabetThe serum concentration of Mirtazapine can be increased when it is combined with Ecabet.
EcgonineEcgonine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EcgonineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ecgonine.
ECGONINE METHYL ESTERECGONINE METHYL ESTER may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Mirtazapine is combined with ECGONINE METHYL ESTER.
EdoxabanThe serum concentration of Mirtazapine can be increased when it is combined with Edoxaban.
EfavirenzEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EfavirenzThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Efavirenz.
ElafinThe serum concentration of Mirtazapine can be increased when it is combined with Elafin.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Mirtazapine.
EliglustatMirtazapine may increase the QTc-prolonging activities of Eliglustat.
EliglustatThe metabolism of Mirtazapine can be decreased when combined with Eliglustat.
EnalaprilThe serum concentration of Mirtazapine can be increased when it is combined with Enalapril.
EnalaprilatThe serum concentration of Mirtazapine can be increased when it is combined with Enalaprilat.
EnalkirenThe serum concentration of Mirtazapine can be increased when it is combined with Enalkiren.
EnfluraneEnflurane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EnfluraneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Enflurane.
EntacaponeEntacapone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EntacaponeThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Entacapone.
EnzalutamideThe serum concentration of Mirtazapine can be decreased when it is combined with Enzalutamide.
EphedraThe therapeutic efficacy of Ephedra can be decreased when used in combination with Mirtazapine.
EpinephrineThe therapeutic efficacy of Epinephrine can be decreased when used in combination with Mirtazapine.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ergoloid mesylate.
ErgonovineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ergonovine.
ErgotamineMirtazapine may increase the vasopressor activities of Ergotamine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Mirtazapine.
ErythromycinMirtazapine may increase the QTc-prolonging activities of Erythromycin.
ErythromycinThe metabolism of Mirtazapine can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Mirtazapine can be decreased when it is combined with Eslicarbazepine acetate.
EstazolamEstazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EstazolamThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Estazolam.
EszopicloneEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EszopicloneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Eszopiclone.
EthanolMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthchlorvynolEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ethchlorvynol.
EthosuximideEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EthosuximideThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ethosuximide.
EthotoinEthotoin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EthotoinThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ethotoin.
Ethyl biscoumacetateMirtazapine may increase the anticoagulant activities of Ethyl biscoumacetate.
Ethyl carbamateEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ethyl carbamate.
Ethyl loflazepateEthyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ethyl loflazepate.
EthylmorphineEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EthylmorphineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ethylmorphine.
EtidocaineEtidocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EtidocaineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Etidocaine.
EtifoxineEtifoxine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EtifoxineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Etifoxine.
EtizolamEtizolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EtizolamThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Etizolam.
EtomidateEtomidate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EtomidateThe therapeutic efficacy of Etomidate can be decreased when used in combination with Mirtazapine.
EtoperidoneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Etoperidone.
EtorphineEtorphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EtorphineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Etorphine.
EtravirineThe serum concentration of Mirtazapine can be decreased when it is combined with Etravirine.
EzogabineEzogabine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
EzogabineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ezogabine.
FelbamateFelbamate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
FelbamateThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Felbamate.
FelodipineThe metabolism of Mirtazapine can be decreased when combined with Felodipine.
FencamfamineFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
FencamfamineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Fenfluramine.
FenoterolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Fenoterol.
FentanylFentanyl may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
FentanylThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Fentanyl.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mirtazapine.
FexofenadineFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
FexofenadineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Fexofenadine.
FlecainideMirtazapine may increase the QTc-prolonging activities of Flecainide.
FlibanserinFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
FlibanserinThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Flibanserin.
FloxuridineThe metabolism of Mirtazapine can be decreased when combined with Floxuridine.
FluconazoleThe metabolism of Mirtazapine can be decreased when combined with Fluconazole.
FludiazepamFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
FludiazepamThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Fludiazepam.
FlunarizineFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
FlunarizineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Flunarizine.
FlunitrazepamFlunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Flunitrazepam.
FluorouracilThe metabolism of Mirtazapine can be decreased when combined with Fluorouracil.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Mirtazapine.
FlupentixolFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
FlupentixolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Flupentixol.
FluphenazineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
FluphenazineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Fluphenazine.
FlurazepamFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
FlurazepamThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Flurazepam.
FluspirileneFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
FluspirileneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Fluspirilene.
Fluticasone PropionateFluticasone Propionate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Mirtazapine can be decreased when combined with Fluvastatin.
FluvoxamineFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
FluvoxamineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Fluvoxamine.
FormoterolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Formoterol.
FosamprenavirThe serum concentration of Mirtazapine can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Mirtazapine can be increased when it is combined with Fosaprepitant.
FosinoprilThe serum concentration of Mirtazapine can be increased when it is combined with Fosinopril.
FosphenytoinFosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
FosphenytoinThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Fosphenytoin.
FospropofolFospropofol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
FospropofolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Frovatriptan.
FurazolidoneFurazolidone may increase the central neurotoxic activities of Mirtazapine.
Fusidic AcidThe serum concentration of Mirtazapine can be increased when it is combined with Fusidic Acid.
GabapentinGabapentin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
GabapentinThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Gabapentin.
gabapentin enacarbilgabapentin enacarbil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Mirtazapine is combined with gabapentin enacarbil.
Gadobenic acidMirtazapine may increase the QTc-prolonging activities of Gadobenic acid.
Gamma Hydroxybutyric AcidGamma Hydroxybutyric Acid may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Gamma Hydroxybutyric Acid.
GeldanamycinThe serum concentration of Mirtazapine can be increased when it is combined with Geldanamycin.
GemfibrozilThe metabolism of Mirtazapine can be decreased when combined with Gemfibrozil.
GemifloxacinMirtazapine may increase the QTc-prolonging activities of Gemifloxacin.
GlutethimideGlutethimide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
GlutethimideThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Glutethimide.
GM6001The serum concentration of Mirtazapine can be increased when it is combined with GM6001.
GoserelinMirtazapine may increase the QTc-prolonging activities of Goserelin.
GranisetronMirtazapine may increase the QTc-prolonging activities of Granisetron.
GranisetronGranisetron may increase the serotonergic activities of Mirtazapine.
GuanabenzThe therapeutic efficacy of Guanabenz can be decreased when used in combination with Mirtazapine.
GuanfacineGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Mirtazapine.
HalazepamHalazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
HalazepamThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Halazepam.
HaloperidolHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
HaloperidolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Haloperidol.
HalothaneHalothane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
HalothaneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Halothane.
HeroinHeroin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
HeroinThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Heroin.
HexobarbitalHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
HexobarbitalThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Hexobarbital.
HirulogThe serum concentration of Mirtazapine can be increased when it is combined with Hirulog.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mirtazapine.
HydracarbazineHydracarbazine may increase the central neurotoxic activities of Mirtazapine.
HydrocodoneHydrocodone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
HydrocodoneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Hydrocodone.
HydromorphoneHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
HydromorphoneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Hydromorphone.
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may decrease the sedative activities of Mirtazapine.
Hydroxyamphetamine hydrobromideMirtazapine may increase the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
HydroxyzineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Hydroxyzine.
IbutilideMirtazapine may increase the QTc-prolonging activities of Ibutilide.
IdelalisibThe serum concentration of Mirtazapine can be increased when it is combined with Idelalisib.
IloperidoneIloperidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
IloperidoneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Iloperidone.
ImatinibThe metabolism of Mirtazapine can be decreased when combined with Imatinib.
ImipramineImipramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ImipramineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Imipramine.
IndacaterolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Indacaterol.
IndalpineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Indalpine.
IndinavirThe serum concentration of Mirtazapine can be increased when it is combined with Indinavir.
IproclozideIproclozide may increase the central neurotoxic activities of Mirtazapine.
IproniazidIproniazid may increase the central neurotoxic activities of Mirtazapine.
IrbesartanThe metabolism of Mirtazapine can be decreased when combined with Irbesartan.
IsavuconazoniumThe metabolism of Mirtazapine can be decreased when combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the central neurotoxic activities of Mirtazapine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Isocarboxazid.
IsoetarineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Isoetarine.
IsofluraneIsoflurane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
IsofluraneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Isoflurane.
IsoflurophateThe serum concentration of Mirtazapine can be increased when it is combined with Isoflurophate.
IsoniazidThe metabolism of Mirtazapine can be decreased when combined with Isoniazid.
IsoprenalineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Isoprenaline.
IsradipineThe metabolism of Mirtazapine can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Mirtazapine can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Mirtazapine can be increased when it is combined with Ivacaftor.
IxazomibThe serum concentration of Mirtazapine can be increased when it is combined with Ixazomib.
KetamineKetamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
KetamineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ketamine.
KetazolamKetazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
KetazolamThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ketazolam.
KetobemidoneKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
KetobemidoneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ketobemidone.
KetoconazoleThe metabolism of Mirtazapine can be decreased when combined with Ketoconazole.
L-TryptophanL-Tryptophan may increase the serotonergic activities of Mirtazapine.
LamotrigineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
LamotrigineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Lamotrigine.
LapatinibThe metabolism of Mirtazapine can be decreased when combined with Lapatinib.
LeflunomideThe metabolism of Mirtazapine can be decreased when combined with Leflunomide.
LenvatinibMirtazapine may increase the QTc-prolonging activities of Lenvatinib.
LepirudinThe serum concentration of Mirtazapine can be increased when it is combined with Lepirudin.
LeuprolideMirtazapine may increase the QTc-prolonging activities of Leuprolide.
LevetiracetamLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
LevetiracetamThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Levetiracetam.
LevobupivacaineLevobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
LevobupivacaineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Levobupivacaine.
LevocabastineLevocabastine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
LevocabastineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Levocabastine.
LevocetirizineLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
LevocetirizineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Levocetirizine.
LevodopaLevodopa may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
LevodopaThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Levodopa.
LevofloxacinMirtazapine may increase the QTc-prolonging activities of Levofloxacin.
Levomethadyl AcetateLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Levomilnacipran.
LevorphanolLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
LevorphanolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Levorphanol.
LevothyroxineLevothyroxine may increase the arrhythmogenic activities of Mirtazapine.
LidocaineLidocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
LidocaineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Lidocaine.
LinagliptinThe serum concentration of Mirtazapine can be increased when it is combined with Linagliptin.
LinezolidLinezolid may increase the serotonergic activities of Mirtazapine.
LinezolidThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Linezolid.
LiothyronineLiothyronine may increase the arrhythmogenic activities of Mirtazapine.
LiotrixLiotrix may increase the arrhythmogenic activities of Mirtazapine.
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Mirtazapine.
LisdexamfetamineMirtazapine may increase the stimulatory activities of Lisdexamfetamine.
LisinoprilThe serum concentration of Mirtazapine can be increased when it is combined with Lisinopril.
LithiumLithium may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
LithiumThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Lithium.
LofentanilLofentanil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
LofentanilThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Lofentanil.
LofexidineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Mirtazapine.
LopinavirThe serum concentration of Mirtazapine can be increased when it is combined with Lopinavir.
LopinavirMirtazapine may increase the QTc-prolonging activities of Lopinavir.
LoratadineLoratadine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
LoratadineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Loratadine.
LorazepamLorazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
LorazepamThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Lorazepam.
LorcaserinThe metabolism of Mirtazapine can be decreased when combined with Lorcaserin.
LorcaserinThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Lorcaserin.
LosartanThe metabolism of Mirtazapine can be decreased when combined with Losartan.
LovastatinThe metabolism of Mirtazapine can be decreased when combined with Lovastatin.
LoxapineLoxapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
LoxapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Loxapine.
Lu AA21004Lu AA21004 may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Lu AA21004The risk or severity of adverse effects can be increased when Mirtazapine is combined with Lu AA21004.
LuliconazoleThe serum concentration of Mirtazapine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Mirtazapine can be decreased when it is combined with Lumacaftor.
LumefantrineMirtazapine may increase the QTc-prolonging activities of Lumefantrine.
LumefantrineThe metabolism of Mirtazapine can be decreased when combined with Lumefantrine.
LurasidoneLurasidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
LurasidoneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Magnesium Sulfate.
MaprotilineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MaprotilineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Maprotiline.
MebanazineMebanazine may increase the central neurotoxic activities of Mirtazapine.
MeclizineMeclizine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MeclizineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Meclizine.
MedetomidineMedetomidine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MedetomidineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Medetomidine.
MelatoninMelatonin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MelatoninThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Melatonin.
MelperoneMelperone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MelperoneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Melperone.
MephentermineMephentermine may decrease the sedative activities of Mirtazapine.
MephentermineMirtazapine may increase the stimulatory activities of Mephentermine.
MepivacaineMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MepivacaineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Mepivacaine.
MeprobamateMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MeprobamateThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Meprobamate.
MesoridazineMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MesoridazineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Mesoridazine.
MetaraminolMirtazapine may increase the vasopressor activities of Metaraminol.
MetaxaloneMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MetaxaloneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Metaxalone.
MethadoneMethadone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MethadoneMirtazapine may increase the QTc-prolonging activities of Methadone.
Methadyl AcetateMethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Methadyl Acetate.
MethamphetamineMethamphetamine may decrease the sedative activities of Mirtazapine.
MethamphetamineMirtazapine may increase the stimulatory activities of Methamphetamine.
MethapyrileneMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MethapyrileneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Methapyrilene.
MethaqualoneMethaqualone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MethaqualoneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Methaqualone.
MethocarbamolMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MethocarbamolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Methocarbamol.
MethohexitalMethohexital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MethohexitalThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Methohexital.
MethotrimeprazineMethotrimeprazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Methotrimeprazine.
MethoxamineMirtazapine may increase the vasopressor activities of Methoxamine.
MethoxyfluraneMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Methoxyflurane.
MethsuximideMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MethsuximideThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Methsuximide.
Methylene blueMethylene blue may increase the central neurotoxic activities of Mirtazapine.
Methylene blueMirtazapine may increase the serotonergic activities of Methylene blue.
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Mirtazapine.
MethylphenobarbitalMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Methylphenobarbital.
MetoclopramideThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Metoclopramide.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Mirtazapine.
MetoprololThe metabolism of Mirtazapine can be decreased when combined with Metoprolol.
MetyrosineMirtazapine may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Mirtazapine.
MexiletineThe metabolism of Mirtazapine can be decreased when combined with Mexiletine.
MidazolamMidazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MidazolamThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Midazolam.
MidodrineMirtazapine may increase the vasopressor activities of Midodrine.
MifepristoneThe metabolism of Mirtazapine can be decreased when combined with Mifepristone.
MifepristoneMirtazapine may increase the QTc-prolonging activities of Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Milnacipran.
MinaprineMinaprine may increase the central neurotoxic activities of Mirtazapine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirabegronThe metabolism of Mirtazapine can be decreased when combined with Mirabegron.
MitotaneThe serum concentration of Mirtazapine can be decreased when it is combined with Mitotane.
MoclobemideMoclobemide may increase the central neurotoxic activities of Mirtazapine.
MoclobemideThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Moclobemide.
ModafinilThe serum concentration of Mirtazapine can be decreased when it is combined with Modafinil.
MoexiprilThe serum concentration of Mirtazapine can be increased when it is combined with Moexipril.
MolindoneMolindone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MolindoneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Molindone.
MorphineMorphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MorphineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Morphine.
MoxifloxacinMirtazapine may increase the QTc-prolonging activities of Moxifloxacin.
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Mirtazapine.
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Mirtazapine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
NabiloneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Nabilone.
NafcillinThe serum concentration of Mirtazapine can be decreased when it is combined with Nafcillin.
NalbuphineNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
NalbuphineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Nalbuphine.
NaphazolineThe therapeutic efficacy of Naphazoline can be decreased when used in combination with Mirtazapine.
NaratriptanThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Naratriptan.
NCX 4016The serum concentration of Mirtazapine can be increased when it is combined with NCX 4016.
NefazodoneThe metabolism of Mirtazapine can be decreased when combined with Nefazodone.
NefazodoneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Nefazodone.
NelfinavirThe serum concentration of Mirtazapine can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Mirtazapine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Mirtazapine can be decreased when combined with Nevirapine.
NialamideNialamide may increase the central neurotoxic activities of Mirtazapine.
NicardipineThe metabolism of Mirtazapine can be decreased when combined with Nicardipine.
NicorandilMirtazapine may increase the hypotensive activities of Nicorandil.
NilotinibThe metabolism of Mirtazapine can be decreased when combined with Nilotinib.
NilotinibMirtazapine may increase the QTc-prolonging activities of Nilotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Mirtazapine.
NitrazepamNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
NitrazepamThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Nitrazepam.
Nitrous oxideNitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Nitrous oxide.
NorepinephrineThe therapeutic efficacy of Norepinephrine can be decreased when used in combination with Mirtazapine.
NormethadoneNormethadone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
NormethadoneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Normethadone.
NortriptylineNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
NortriptylineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Nortriptyline.
OctamoxinOctamoxin may increase the central neurotoxic activities of Mirtazapine.
OfloxacinMirtazapine may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
OlanzapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Olanzapine.
OlaparibThe metabolism of Mirtazapine can be decreased when combined with Olaparib.
OlodaterolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Olodaterol.
OlopatadineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
OlopatadineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Olopatadine.
OmapatrilatThe serum concentration of Mirtazapine can be increased when it is combined with Omapatrilat.
OmeprazoleThe metabolism of Mirtazapine can be decreased when combined with Omeprazole.
OndansetronOndansetron may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
OndansetronThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ondansetron.
OpiumOpium may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
OpiumThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Opium.
OrciprenalineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Orciprenaline.
OrphenadrineOrphenadrine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
OsanetantOsanetant may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
OsanetantThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Osanetant.
OsimertinibThe serum concentration of Mirtazapine can be increased when it is combined with Osimertinib.
OtamixabanThe serum concentration of Mirtazapine can be increased when it is combined with Otamixaban.
OxazepamOxazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
OxazepamThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Oxazepam.
OxprenololOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
OxprenololThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Oxprenolol.
OxybuprocaineOxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Oxybuprocaine.
OxycodoneOxycodone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
OxycodoneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Oxycodone.
OxymetazolineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Mirtazapine.
OxymorphoneOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
OxymorphoneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Oxymorphone.
PalbociclibThe serum concentration of Mirtazapine can be increased when it is combined with Palbociclib.
PaliperidonePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PaliperidoneThe therapeutic efficacy of Paliperidone can be decreased when used in combination with Mirtazapine.
PalonosetronPalonosetron may increase the serotonergic activities of Mirtazapine.
PanobinostatMirtazapine may increase the QTc-prolonging activities of Panobinostat.
PanobinostatThe metabolism of Mirtazapine can be decreased when combined with Panobinostat.
ParaldehydeParaldehyde may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PargylinePargyline may increase the central neurotoxic activities of Mirtazapine.
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Mirtazapine.
PazopanibMirtazapine may increase the QTc-prolonging activities of Pazopanib.
Peginterferon alfa-2bThe serum concentration of Mirtazapine can be decreased when it is combined with Peginterferon alfa-2b.
PentamidineMirtazapine may increase the QTc-prolonging activities of Pentamidine.
PentazocinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PentazocineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Pentazocine.
PentobarbitalPentobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PentobarbitalThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Pentobarbital.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PerampanelThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Perampanel.
PerflutrenMirtazapine may increase the QTc-prolonging activities of Perflutren.
PergolideThe therapeutic efficacy of Pergolide can be decreased when used in combination with Mirtazapine.
PerindoprilThe serum concentration of Mirtazapine can be increased when it is combined with Perindopril.
PerospironePerospirone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PerospironeThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Perospirone.
PerphenazinePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PerphenazineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Perphenazine.
PethidinePethidine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PethidineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Pethidine.
PhenelzinePhenelzine may increase the central neurotoxic activities of Mirtazapine.
PhenelzineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Phenelzine.
PhenindioneMirtazapine may increase the anticoagulant activities of Phenindione.
PheniprazinePheniprazine may increase the central neurotoxic activities of Mirtazapine.
PhenobarbitalPhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Phenobarbital.
PhenoxyethanolPhenoxyethanol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Phenoxyethanol.
PhenoxypropazinePhenoxypropazine may increase the central neurotoxic activities of Mirtazapine.
PhenprocoumonMirtazapine may increase the anticoagulant activities of Phenprocoumon.
PhenterminePhentermine may decrease the sedative activities of Mirtazapine.
PhentermineMirtazapine may increase the stimulatory activities of Phentermine.
PhenylephrineMirtazapine may increase the vasopressor activities of Phenylephrine.
PhenylpropanolamineThe therapeutic efficacy of Phenylpropanolamine can be decreased when used in combination with Mirtazapine.
PhenytoinPhenytoin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PhenytoinThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Phenytoin.
PhosphoramidonThe serum concentration of Mirtazapine can be increased when it is combined with Phosphoramidon.
PimozidePimozide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PimozideThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Pimozide.
PioglitazoneThe metabolism of Mirtazapine can be decreased when combined with Pioglitazone.
PipamperonePipamperone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PipamperoneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Pipamperone.
PipotiazinePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PipotiazineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Pipotiazine.
PirbuterolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Pirbuterol.
PirlindolePirlindole may increase the central neurotoxic activities of Mirtazapine.
PivhydrazinePivhydrazine may increase the central neurotoxic activities of Mirtazapine.
PizotifenPizotifen may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PizotifenThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Pizotifen.
PomalidomidePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PomalidomideThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Pomalidomide.
PosaconazoleThe metabolism of Mirtazapine can be decreased when combined with Posaconazole.
PramipexoleMirtazapine may increase the sedative activities of Pramipexole.
PramocainePramocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PramocaineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Pramocaine.
PrazepamPrazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PrazepamThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Prazepam.
PregabalinPregabalin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PregabalinThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Pregabalin.
PrilocainePrilocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PrilocaineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Prilocaine.
PrimaquineMirtazapine may increase the QTc-prolonging activities of Primaquine.
PrimidonePrimidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PrimidoneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Primidone.
PrinomastatThe serum concentration of Mirtazapine can be increased when it is combined with Prinomastat.
ProcainamideMirtazapine may increase the QTc-prolonging activities of Procainamide.
ProcaineProcaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ProcaineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Procaine.
ProcarbazineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Procarbazine.
ProcaterolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Procaterol.
ProchlorperazineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Prochlorperazine.
PromazinePromazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PromazineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Promazine.
PromethazinePromethazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PromethazineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Promethazine.
PropafenoneMirtazapine may increase the QTc-prolonging activities of Propafenone.
ProparacaineProparacaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ProparacaineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Proparacaine.
PropericiazineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Propericiazine.
PropofolPropofol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PropofolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Propofol.
PropoxycainePropoxycaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PropoxycaineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Propoxycaine.
ProtriptylineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ProtriptylineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Protriptyline.
PSD502PSD502 may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
PSD502The risk or severity of adverse effects can be increased when Mirtazapine is combined with PSD502.
PseudoephedrineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Mirtazapine.
PyrimethamineThe metabolism of Mirtazapine can be decreased when combined with Pyrimethamine.
QuazepamQuazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
QuazepamThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Quazepam.
QuetiapineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
QuetiapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Quetiapine.
QuinaprilThe serum concentration of Mirtazapine can be increased when it is combined with Quinapril.
QuinidineMirtazapine may increase the QTc-prolonging activities of Quinidine.
QuinidineThe metabolism of Mirtazapine can be decreased when combined with Quinidine.
QuinineMirtazapine may increase the QTc-prolonging activities of Quinine.
QuinineThe metabolism of Mirtazapine can be decreased when combined with Quinine.
RabeprazoleThe metabolism of Mirtazapine can be decreased when combined with Rabeprazole.
RamelteonRamelteon may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
RamelteonThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ramelteon.
RamiprilThe serum concentration of Mirtazapine can be increased when it is combined with Ramipril.
RanolazineThe metabolism of Mirtazapine can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the central neurotoxic activities of Mirtazapine.
RasagilineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Rasagiline.
RemifentanilRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
RemifentanilThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Remifentanil.
RemikirenThe serum concentration of Mirtazapine can be increased when it is combined with Remikiren.
RemoxiprideRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
RemoxiprideThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Remoxipride.
ReserpineReserpine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ReserpineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Reserpine.
RifabutinThe metabolism of Mirtazapine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Mirtazapine can be increased when combined with Rifampicin.
RifapentineThe metabolism of Mirtazapine can be increased when combined with Rifapentine.
RisperidoneRisperidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
RisperidoneThe therapeutic efficacy of Risperidone can be decreased when used in combination with Mirtazapine.
RitodrineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ritodrine.
RitonavirThe serum concentration of Mirtazapine can be increased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Mirtazapine can be increased when it is combined with Rivaroxaban.
RizatriptanThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Rizatriptan.
RolapitantThe metabolism of Mirtazapine can be decreased when combined with Rolapitant.
RomifidineRomifidine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
RomifidineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Romifidine.
RopiniroleMirtazapine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Mirtazapine can be decreased when combined with Ropinirole.
RopivacaineRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
RopivacaineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ropivacaine.
RosiglitazoneThe metabolism of Mirtazapine can be decreased when combined with Rosiglitazone.
RotigotineMirtazapine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Mirtazapine.
S-EthylisothioureaS-Ethylisothiourea may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Mirtazapine is combined with S-Ethylisothiourea.
SafrazineSafrazine may increase the central neurotoxic activities of Mirtazapine.
SalbutamolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Salbutamol.
SalmeterolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Salmeterol.
SaquinavirThe serum concentration of Mirtazapine can be increased when it is combined with Saquinavir.
SaquinavirMirtazapine may increase the QTc-prolonging activities of Saquinavir.
SaxagliptinThe serum concentration of Mirtazapine can be increased when it is combined with Saxagliptin.
ScopolamineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ScopolamineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Scopolamine.
SecobarbitalSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
SecobarbitalThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Secobarbital.
SelegilineSelegiline may increase the central neurotoxic activities of Mirtazapine.
SelegilineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Selegiline.
SertindoleSertindole may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
SertindoleThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Sertraline.
SertralineThe metabolism of Mirtazapine can be decreased when combined with Sertraline.
SevofluraneSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
SevofluraneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Sevoflurane.
SildenafilThe metabolism of Mirtazapine can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Mirtazapine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Mirtazapine can be increased when it is combined with Simeprevir.
SitagliptinThe serum concentration of Mirtazapine can be increased when it is combined with Sitagliptin.
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Sodium oxybate.
SorafenibThe metabolism of Mirtazapine can be decreased when combined with Sorafenib.
SotalolMirtazapine may increase the QTc-prolonging activities of Sotalol.
SpiraprilThe serum concentration of Mirtazapine can be increased when it is combined with Spirapril.
St. John's WortThe serum concentration of Mirtazapine can be decreased when it is combined with St. John's Wort.
StiripentolStiripentol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
StiripentolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Stiripentol.
SufentanilSufentanil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
SufentanilThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Sufentanil.
SulfadiazineThe metabolism of Mirtazapine can be decreased when combined with Sulfadiazine.
SulfamethoxazoleThe metabolism of Mirtazapine can be decreased when combined with Sulfamethoxazole.
SulfisoxazoleMirtazapine may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Mirtazapine can be decreased when combined with Sulfisoxazole.
SulpirideSulpiride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
SulpirideThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Sumatriptan.
SuvorexantSuvorexant may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
SuvorexantThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Suvorexant.
TamoxifenThe metabolism of Mirtazapine can be decreased when combined with Tamoxifen.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TapentadolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Tapentadol.
TasimelteonTasimelteon may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TasimelteonThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Tasimelteon.
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Mirtazapine.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Tedizolid Phosphate.
TelaprevirThe serum concentration of Mirtazapine can be increased when it is combined with Telaprevir.
TelavancinMirtazapine may increase the QTc-prolonging activities of Telavancin.
TelithromycinMirtazapine may increase the QTc-prolonging activities of Telithromycin.
TelithromycinThe metabolism of Mirtazapine can be decreased when combined with Telithromycin.
TemazepamTemazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TemazepamThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Temazepam.
TemocaprilThe serum concentration of Mirtazapine can be increased when it is combined with Temocapril.
TenofovirThe metabolism of Mirtazapine can be decreased when combined with Tenofovir.
TerbinafineThe metabolism of Mirtazapine can be decreased when combined with Terbinafine.
TerbutalineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Terbutaline.
TeriflunomideThe serum concentration of Mirtazapine can be decreased when it is combined with Teriflunomide.
TetrabenazineTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TetrabenazineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Tetrabenazine.
TetracaineTetracaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TetracaineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Tetracaine.
TetrodotoxinTetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Tetrodotoxin.
ThalidomideThalidomide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TheophyllineThe metabolism of Mirtazapine can be decreased when combined with Theophylline.
ThiamylalThiamylal may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ThiamylalThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Thiamylal.
ThiopentalThiopental may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ThiopentalThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Thiopental.
ThioproperazineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Thioproperazine.
ThioridazineThioridazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Mirtazapine.
ThiorphanThe serum concentration of Mirtazapine can be increased when it is combined with Thiorphan.
ThiothixeneThiothixene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ThiothixeneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Thiothixene.
Thyroid, porcineThyroid, porcine may increase the arrhythmogenic activities of Mirtazapine.
TiagabineTiagabine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TiagabineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Tiagabine.
TicagrelorThe metabolism of Mirtazapine can be decreased when combined with Ticagrelor.
TiclopidineThe metabolism of Mirtazapine can be decreased when combined with Ticlopidine.
TiletamineTiletamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TiletamineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Tiletamine.
TipranavirThe serum concentration of Mirtazapine can be increased when it is combined with Tipranavir.
TizanidineTizanidine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TizanidineThe therapeutic efficacy of Tizanidine can be decreased when used in combination with Mirtazapine.
TocilizumabThe serum concentration of Mirtazapine can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Mirtazapine can be decreased when combined with Tolbutamide.
TolcaponeTolcapone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TolcaponeThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Tolcapone.
ToloxatoneToloxatone may increase the central neurotoxic activities of Mirtazapine.
TopiramateTopiramate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TopiramateThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Topiramate.
ToremifeneMirtazapine may increase the QTc-prolonging activities of Toremifene.
TramadolTramadol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TramadolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Tramadol.
TrandolaprilThe serum concentration of Mirtazapine can be increased when it is combined with Trandolapril.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the central neurotoxic activities of Mirtazapine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineTranylcypromine may increase the central neurotoxic activities of Mirtazapine.
TranylcypromineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Tranylcypromine.
TrazodoneTrazodone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TrazodoneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Trazodone.
TriazolamTriazolam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TriazolamThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Triazolam.
TrifluoperazineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Trifluoperazine.
TriflupromazineTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TriflupromazineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Triflupromazine.
TrimethoprimThe metabolism of Mirtazapine can be decreased when combined with Trimethoprim.
TrimipramineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TrimipramineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Trimipramine.
TriprolidineTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
TriprolidineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Triprolidine.
UbenimexThe serum concentration of Mirtazapine can be increased when it is combined with Ubenimex.
Valproic AcidValproic Acid may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Valproic AcidThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Valproic Acid.
ValsartanThe metabolism of Mirtazapine can be decreased when combined with Valsartan.
VandetanibMirtazapine may increase the QTc-prolonging activities of Vandetanib.
VemurafenibThe serum concentration of Mirtazapine can be increased when it is combined with Vemurafenib.
VemurafenibMirtazapine may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe metabolism of Mirtazapine can be decreased when combined with Venlafaxine.
VenlafaxineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Venlafaxine.
VerapamilThe metabolism of Mirtazapine can be decreased when combined with Verapamil.
VigabatrinVigabatrin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
VigabatrinThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Vigabatrin.
VilanterolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Vilanterol.
VilazodoneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Vilazodone.
VildagliptinThe serum concentration of Mirtazapine can be increased when it is combined with Vildagliptin.
VoriconazoleThe metabolism of Mirtazapine can be decreased when combined with Voriconazole.
VortioxetineVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
VortioxetineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Vortioxetine.
WarfarinMirtazapine may increase the anticoagulant activities of Warfarin.
XimelagatranThe serum concentration of Mirtazapine can be increased when it is combined with Ximelagatran.
XylazineXylazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
XylazineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Xylazine.
XylometazolineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Mirtazapine.
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Mirtazapine.
ZafirlukastThe metabolism of Mirtazapine can be decreased when combined with Zafirlukast.
ZaleplonZaleplon may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ZaleplonThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Zaleplon.
ZiconotideZiconotide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ZiconotideThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Zimelidine.
ZiprasidoneZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Ziprasidone.
ZolazepamZolazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ZolazepamThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Mirtazapine.
ZolpidemZolpidem may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ZolpidemThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Zolpidem.
ZonisamideZonisamide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ZonisamideThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Zonisamide.
ZopicloneZopiclone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ZopicloneThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Zopiclone.
ZotepineZotepine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ZotepineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Zotepine.
ZuclopenthixolZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Zuclopenthixol.
Food Interactions
  • Take without regard to meals. Avoid alcohol.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Westenberg HG: Pharmacology of antidepressants: selectivity or multiplicity? J Clin Psychiatry. 1999;60 Suppl 17:4-8; discussion 46-8. [PubMed:10446734 ]
  2. Gorman JM: Mirtazapine: clinical overview. J Clin Psychiatry. 1999;60 Suppl 17:9-13; discussion 46-8. [PubMed:10446735 ]
  3. Nutt DJ: Care of depressed patients with anxiety symptoms. J Clin Psychiatry. 1999;60 Suppl 17:23-7; discussion 46-8. [PubMed:10446738 ]
  4. Laakmann G, Schule C, Baghai T, Waldvogel E: Effects of mirtazapine on growth hormone, prolactin, and cortisol secretion in healthy male subjects. Psychoneuroendocrinology. 1999 Oct;24(7):769-84. [PubMed:10451911 ]
  5. Waldinger MD, Berendsen HH, Schweitzer DH: Treatment of hot flushes with mirtazapine: four case reports. Maturitas. 2000 Oct 31;36(3):165-8. [PubMed:11063897 ]
  6. Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64. [PubMed:11607047 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Voltage-gated potassium channel activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
Gene Name:
HTR3A
Uniprot ID:
P46098
Molecular Weight:
55279.835 Da
References
  1. Westenberg HG: Pharmacology of antidepressants: selectivity or multiplicity? J Clin Psychiatry. 1999;60 Suppl 17:4-8; discussion 46-8. [PubMed:10446734 ]
  2. Gorman JM: Mirtazapine: clinical overview. J Clin Psychiatry. 1999;60 Suppl 17:9-13; discussion 46-8. [PubMed:10446735 ]
  3. Kast RE, Foley KF: Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects. Eur J Cancer Care (Engl). 2007 Jul;16(4):351-4. [PubMed:17587360 ]
  4. de Boer T: The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol. 1995 Dec;10 Suppl 4:19-23. [PubMed:8930006 ]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  6. Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64. [PubMed:11607047 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Garcia-Sevilla JA, Ventayol P, Perez V, Rubovszky G, Puigdemont D, Ferrer-Alcon M, Andreoli A, Guimon J, Alvarez E: Regulation of platelet alpha 2A-adrenoceptors, Gi proteins and receptor kinases in major depression: effects of mirtazapine treatment. Neuropsychopharmacology. 2004 Mar;29(3):580-8. [PubMed:14628003 ]
  2. Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64. [PubMed:11607047 ]
  3. Besson A, Haddjeri N, Blier P, de Montigny C: Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain. Eur Neuropsychopharmacol. 2000 May;10(3):177-88. [PubMed:10793320 ]
  4. Schreiber S, Bleich A, Pick CG: Venlafaxine and mirtazapine: different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects--a possible opioid involvement in severe depression? J Mol Neurosci. 2002 Feb-Apr;18(1-2):143-9. [PubMed:11931344 ]
  5. Rogoz Z, Wrobel A, Dlaboga D, Maj J, Dziedzicka-Wasylewska M: Effect of repeated treatment with mirtazapine on the central alpha1-adrenergic receptors. J Physiol Pharmacol. 2002 Mar;53(1):105-16. [PubMed:11939713 ]
  6. Rogoz Z, Wrobel A, Dlaboga D, Dziedzicka-Wasylewska M: Effect of repeated treatment with mirtazapine on the central dopaminergic D2/D3 receptors. Pol J Pharmacol. 2002 Jul-Aug;54(4):381-9. [PubMed:12523492 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Benelli A, Frigeri C, Bertolini A, Genedani S: Influence of mirtazapine on the sexual behavior of male rats. Psychopharmacology (Berl). 2004 Jan;171(3):250-8. Epub 2003 Nov 13. [PubMed:14615872 ]
  2. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F: Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. 2000 Mar;12(3):1079-95. [PubMed:10762339 ]
  3. Meert TF, Melis W, Aerts N, Clincke G: Antagonism of meta-chlorophenylpiperazine-induced inhibition of exploratory activity in an emergence procedure, the open field test, in rats. Behav Pharmacol. 1997 Aug;8(4):353-63. [PubMed:9832994 ]
  4. Millan MJ: Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie. 2005 Sep-Oct;60(5):441-60. [PubMed:16433010 ]
  5. Dekeyne A, Iob L, Millan MJ: Following long-term training with citalopram, both mirtazapine and mianserin block its discriminative stimulus properties in rats. Psychopharmacology (Berl). 2001 Jan;153(3):389-92. [PubMed:11271412 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Schreiber S, Rigai T, Katz Y, Pick CG: The antinociceptive effect of mirtazapine in mice is mediated through serotonergic, noradrenergic and opioid mechanisms. Brain Res Bull. 2002 Sep 30;58(6):601-5. [PubMed:12372565 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Protein homodimerization activity
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name:
ADRA2C
Uniprot ID:
P18825
Molecular Weight:
49521.585 Da
References
  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415 ]
  2. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. [PubMed:3419539 ]
  3. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binding
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Molecular Weight:
53554.43 Da
References
  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415 ]
  2. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. [PubMed:3419539 ]
  3. PDSP Ki Database [Link]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Components:
NameUniProt IDDetails
Alpha-1A adrenergic receptorP35348 Details
Alpha-1B adrenergic receptorP35368 Details
Alpha-1D adrenergic receptorP25100 Details
References
  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415 ]
  2. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. [PubMed:3419539 ]
  3. Wikstrom HV, Mensonides-Harsema MM, Cremers TI, Moltzen EK, Arnt J: Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine. J Med Chem. 2002 Jul 18;45(15):3280-5. [PubMed:12109911 ]
  4. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Wikstrom HV, Mensonides-Harsema MM, Cremers TI, Moltzen EK, Arnt J: Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine. J Med Chem. 2002 Jul 18;45(15):3280-5. [PubMed:12109911 ]
  2. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415 ]
  3. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. [PubMed:3419539 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Wikstrom HV, Mensonides-Harsema MM, Cremers TI, Moltzen EK, Arnt J: Synthesis and pharmacological testing of 1,2,3,4,10,14b-hexahydro-6-methoxy-2-methyldibenzo[c,f]pyrazino[1,2-a]azepin and its enantiomers in comparison with the two antidepressants mianserin and mirtazapine. J Med Chem. 2002 Jul 18;45(15):3280-5. [PubMed:12109911 ]
  2. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415 ]
  3. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. [PubMed:3419539 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415 ]
  2. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415 ]
  2. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415 ]
  2. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various ergot alkaloid derivatives and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Beta-arrestin family members inhibit signaling via G proteins ...
Gene Name:
HTR2B
Uniprot ID:
P41595
Molecular Weight:
54297.41 Da
References
  1. de Boer T: The pharmacologic profile of mirtazapine. J Clin Psychiatry. 1996;57 Suppl 4:19-25. [PubMed:8636062 ]
  2. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415 ]
  3. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. [PubMed:3419539 ]
  4. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F: Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. 2000 Mar;12(3):1079-95. [PubMed:10762339 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Components:
NameUniProt IDDetails
D(1A) dopamine receptorP21728 Details
D(1B) dopamine receptorP21918 Details
References
  1. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415 ]
  2. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. [PubMed:3419539 ]
  3. de Boer T: The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol. 1995 Dec;10 Suppl 4:19-23. [PubMed:8930006 ]
  4. PDSP Ki Database [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
The H3 subclass of histamine receptors could mediate the histamine signals in CNS and peripheral nervous system. Signals through the inhibition of adenylate cyclase and displays high constitutive activity (spontaneous activity in the absence of agonist). Agonist stimulation of isoform 3 neither modified adenylate cyclase activity nor induced intracellular calcium mobilization.
Gene Name:
HRH3
Uniprot ID:
Q9Y5N1
Molecular Weight:
48670.81 Da
References
  1. Pytliak M, Vargova V, Mechirova V, Felsoci M: Serotonin receptors - from molecular biology to clinical applications. Physiol Res. 2011;60(1):15-25. Epub 2010 Oct 15. [PubMed:20945968 ]
  2. Fernandez J, Alonso JM, Andres JI, Cid JM, Diaz A, Iturrino L, Gil P, Megens A, Sipido VK, Trabanco AA: Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents. J Med Chem. 2005 Mar 24;48(6):1709-12. [PubMed:15771415 ]
  3. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM: Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers. Neuropharmacology. 1988 Apr;27(4):399-408. [PubMed:3419539 ]
  4. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F: Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. 2000 Mar;12(3):1079-95. [PubMed:10762339 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F: Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. 2000 Mar;12(3):1079-95. [PubMed:10762339 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Molecular Weight:
51322.1 Da
References
  1. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F: Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. 2000 Mar;12(3):1079-95. [PubMed:10762339 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine.
Gene Name:
ADRB2
Uniprot ID:
P07550
Molecular Weight:
46458.32 Da
References
  1. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F: Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram. Eur J Neurosci. 2000 Mar;12(3):1079-95. [PubMed:10762339 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64. [PubMed:11607047 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Stormer E, von Moltke LL, Shader RI, Greenblatt DJ: Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos. 2000 Oct;28(10):1168-75. [PubMed:10997935 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64. [PubMed:11607047 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Stormer E, von Moltke LL, Shader RI, Greenblatt DJ: Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos. 2000 Oct;28(10):1168-75. [PubMed:10997935 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Anttila SA, Leinonen EV: A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev. 2001 Fall;7(3):249-64. [PubMed:11607047 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Stormer E, von Moltke LL, Shader RI, Greenblatt DJ: Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos. 2000 Oct;28(10):1168-75. [PubMed:10997935 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23